| MATERIAL S AND ME THODS

| Patient selection, procedures and follow-up
A retrospective review of oligometastatic (≤3 concurrent metastases) patients treated at our Institution between May 2005 and September 2016 with stereotactic radiotherapy for at least one bone metastasis was performed after obtainment of informed consent. Pain at the treated site was evaluated at baseline and during clinical follow-up after treatment using the Numeric Rating Scale (NRS) and Visual Analog Scale (VAS; Paice & Cohen, 1997) .
In patient with NRS ≥ 2 at baseline, active pain was further classified using the ECS-CP 5 items tool. Pain medications were classified according to the WHO three-step ladder, consisting of step 1 drugs (paracetamol, NSAIDs), step 2 drugs (mild opioids: codeine, dihydrocodeine or tramadol) and step 3 drugs (strong opioids: morphine, fentanyl, buprenorphine, oxymorphone, oxycodone or hydromorphone; WHO's Pain Ladder, 1986) . Stereotactic treatment was delivered using the CyberKnife radiotherapy system (Accuray Inc, Sunnyvale, CA). Volumes delineation and dose calculation were performed using the Multiplan Treatment Planning System. The gross tumour volume (GTV) was identified as the visible lesion on fused diagnostic imaging (MRI, contrast-enhanced CT or PET-CT). Planning target volume (PTV) included the GTV or, if present, the CTV plus a 2-5 mm margin. Before 2012, the PTV for spinal metastases equalled to the GTV plus a 2-3 mm margin, and after 2012, volumes were delineated according to the ISRC consensus recommendations (Cox et al., 2012) . The total dose was prescribed to the outer line of the PTV to the 80%-90% isodose line using different single or multiple fraction schedules. Dose constraints for OARs were applied according to the American Association of Physicists in Medicine (AAPM) recommendations (Benedict et al., 2010) . To take into account different dose fractionation, all the dosimetric variables were recalculated as equivalent dose in 2 Gy (EQD2) with an α/β = 10 and 3 for early and late reacting tissues respectively. For every treatment, patient-related data (age, gender, primary tumour, ECOG performance status, prior chemotherapy, number of metastases, spinal/extraspinal localisation, lytic/solid/ mixed radiological aspect, pain at baseline, use and dosage of analgesics, use and dosage of steroids) and radiotherapy-related data (single/multiple fraction dose schedule, total dose delivered, GTV and PTV volume, minimum dose to the PTV, maximum dose to the PTV, mean dose to the PTV) were collected. Likewise, opioids and steroid dosage (in milligrams) were reconverted in oral-morphine equivalent (OME) and dexamethasone equivalent (DXE) to allow for comparison. According to institutional guidelines, follow-up visits were scheduled at 1, 3 and 6 months and subsequently once a year. All procedures in our study were performed in accordance with the ethical standards of the National Research Committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
| Definition of endpoints
Pain flare was defined as a temporary (resolving within subsequent clinical evaluation) ≥2-points increase in the NRS pain scale compared to baseline levels with no decrease in analgesic intake or +25% increase in analgesic intake with no decrease in pain score (Chow, Ling, Davis, Panzarella, & Danjoux, 2005) .
Pain progression (PP) was defined as durable increase of pain score of ≥2 points above baseline at the treated metastatic site with stable analgesic use or increase ≥25% in daily oral-morphine equivalent compared with pretreatment intake, with stable pain score (Chow et al., 2005) . Pain control (PC) was defined as time from treatment start date to PP. Overall survival (OS) was measured from start of the radiation therapy until death from any cause.
| Statistical analysis
Descriptive statistics were used to report patient-and treatment-related characteristics as mean and median with range for continuous variables and as proportions for categorical variables. To search for the relationship between pain flare and predictive factors, continuous parametric and non-parametric variables were tested with t test and Mann-Whitney test, respectively, while chi-square test was used for categorical variables. Time-related events such as PC and OS were plotted using the Kaplan-Meier method; correlation with pretreatment was tested using the log-rank test. A p-value ≤0.05 was considered statistically significant. Statistical analysis was performed with IBM SPSS v.21 statistical software.
| RE SULTS
| Patient-and treatment-related characteristics
A total number of 48 patients with 54 lesions were included in the study. The most represented primary tumour was breast adenocarcinoma, accounting for 21/54 metastases (39%) in 17/48 patients (35%). Bone was the only metastatic site in 36 patients out of 48 (75%); 6 patients simultaneously received SBRT to two bone metastases. Bone metastases were predominantly located in the spine (n = 32, 59%), the pelvis (n = 10, 19%), the ribs (n = 7, 13%), the limbs (n = 4, 7%) and in the skull (n = 1, 2%). A pain level equal or superior to 2 in the NRS scale was present in 23 out of 48 patients, (48%) all of whom treated for a single lesion. Daily intake of pain medications was found in 21 painful patients, consisting of step 1, step 2 and step 3 drugs in 7, 3 and 11 patients respectively. In patients requiring step 3 medication, median prescribed dose was 40 mg OME (5-460 mg OME). Prescription of prophylactic steroid treatment was found in 10 patients, receiving a median dose of 8 mg DXE (3-16 mg DXE).
Use of steroids was more frequent in patients with concurrent opioid-based pain medication (p = 0.02). Patient-related characteristics are reported in Table 1 .
Presence of pain complexity indicators was evaluated according
to the ECS-CP tool in 23 patients with active pain before treatment (Table 2 ). Presence of incident pain was the most prominent ECS-CP feature (35%), while no cognitive dysfunction was found in our cohort.
At least one item was found positive in 13 patients, while five patients showed two or more ECS-CP features. No item or combination of items was correlated with administration of steroids or opioids, except for psychological distress that was correlated with higher steroid intake (p = 0.008). Note. DXE: dexamethasone equivalent (in mg); OME: Oral-morphine equivalent (in mg).
TA B L E 1 (Continued) Figure S1 . The size of the GTV was correlated at univariate analysis with active pain in the treated site (p < 0.001) and consequently with prescription of pain medication (p < 0.001) and in particular opioids (p = 0.005). 
| Pain flare
| D ISCUSS I ON
Pain flare was a frequent side effect of SBRT and was found in more than one third of patients in our series. The occurrence of pain flare is a common acute adverse effect in patients treated with CRT palliative dose schedules, with reported incidence up to 40% (Chow et TA B L E 2 Pain complexity according to ECS-CP (per patient and per treatment site) and correlation with steroid use, opioid medication and pain progression in patients with active pain at baseline (Gomez-Iturriaga et al., 2015) . The cumulative incidence of pain flare ranged between 23%-68% (Chiang et al., 2013; Pan et al., 2014) when patients were treated for a spinal metastases and was 10% for extraspinal sites (Owen et al., 2014 ). According to current literature, known predictors of pain flare onset are single-fraction dose regimen (Pan et al., 2014) and lack of steroid pretreatment (Khan et al., 2015) .
Interestingly, no differences in terms of incidence of pain flare were found between patient groups, most notably for whom it concerns dose schedule and prior administration of steroid premedication. In however, longer follow-up might be needed to confirm the absence of chronic complications such as myelopathy and fractures.
We also focused on the subset of patients who presented with active pain at baseline evaluation to further characterise their conditions and to identify predictors of impaired pain control. As expected, only the size of the target lesion was correlated with the probability to develop pain. In addition to patients and treatmentderived variables, we investigated the use and prognostic value of the ECS-CP, a validated tool developed to study pain complexity in cancer patients and, consequently, difficulty in achieving adequate analgesia. Four out of five items that compose the tool were correctly identified in our cohort; only cognitive impairment was not found in any patients, probably due to scarce compliance of those patients to the stringent requirements of SBRT that resulted in selection of patients with preserved cognitive function.
Conversely, addiction to alcohol and cannabis was found in one case. Incident pain (n = 8) and neuropathic component (n = 6)
were the most frequently identified complexity indicators, while psychological distress linked to pain-related aspects of the disease was assessed in four patients. Interestingly, the presence of ≥2 ECS-CP complexity indicators was correlated to shorter pain control, resulting in a time to pain progression of 4 months vs.
30 months. There is a lack of data concerning the applicability of the ECS-CP tool in the pain outcome after radiotherapy to painful metastases. However, if further assessment is warranted in larger prospective cohorts, the ECS-CP may prove useful to stratify patients in function of the expected benefit from radiotherapy and to identify other critical areas of intervention (such as pharmacological/neurosurgical management of neuropathic pain, early diagnosis and counselling for psychological distress, and management of addictive behaviours) in order to overcome pain complexity and obtain adequate analgesia.
Pain control at 1 year was maintained in 62% of patients with active pain prior to SBRT. Data from literature show pain control in 27%-100% of patients at 6 months (Chang, Youn, Park, & Rhee, 2009; Gibbs & Radiosurgery, 2003; Wang et al., 2012) and 54%-85% (Nguyen et al., 2010; Sheehan et al., 2009) is noteworthy that, in our cohort, median survival after SBRT was 39 months, with only 12% of patients deceasing within 6 months of the treatment. Due to expected long survival, it is mandatory to obtain durable pain control in metastatic patients and to consider multidisciplinary management to achieve this goal, even in case of treatment failure (Mercadante & Fulfaro, 2007) :For example, surgical rescue was possible in two patients with painful bone progression after SBRT.
There are several limitations in our study. In first instance, its retrospective design with subsequent risk of bias due to data loss, 
| CON CLUS IONS
In patients affected by bone metastases treated by SBRT, pain flare was observed in 38% of cases irrespectively of steroid premedication and dose regimen. In patient with active pain at baseline, pain control was obtained in 62% of patients at 1 year. Presence of ≥2 complexity indicators at the ECS-CP assessment was correlated with impaired pain control and may deserve future investigation in prospective studies.
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